Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UKT-CART19.1 in relapsed/refractory autoimmune diseases
2024-519491-60-00Phase 2Authorised
- Sponsor
- University Hospital Tübingen
- Start
- Aug 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of UKT-CART19.1 in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), immune thrombocytopenia (ITP), multiple sclerosis (MS) and 4 more, sponsored by University Hospital Tübingen. Planned start Aug 2026; status: authorised.
02
Drugs
UKT-CART19.1
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)immune thrombocytopenia (ITP)multiple sclerosis (MS)rheumatoid arthritis (RA)pemphigus vulgaris (PV)
Beyond the preview
Go deeper on 2024-519491-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519491-60-00.